Articles From: ACETO Corporation Schedules Second Quarter Fiscal 2015 Financial Results News Release and Conference Call to Acorda Therapeutics to Present at the Cowen 35th Annual Health Care Conference


2015/1/26
PORT WASHINGTON, N.Y., Jan.
Sign-up for ACETO Corporation Schedules Second Quarter Fiscal 2015 Financial Results News Release and Conference Call investment picks
2014/12/4
PORT WASHINGTON, N.Y., Dec.
Sign-up for ACETO Receives SEC Approval to Change its SIC Code to 5122 investment picks
2015/2/5
PORT WASHINGTON, N.Y., Feb.
Sign-up for ACETO Reports Second Quarter Fiscal 2015 Results investment picks
2015/1/8
SOUTH SAN FRANCISCO, Calif., Jan.
Sign-up for Achaogen Announces Plazomicin Granted QIDP Designation by FDA investment picks
2015/2/9
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV - NEW HAVEN, Conn., Feb.
Sign-up for Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102 investment picks
2015/2/18
NEW HAVEN, Conn., Feb.
Sign-up for Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock investment picks
2015/2/11
NEW HAVEN, Conn., Feb.
Sign-up for Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock investment picks
2015/2/10
NEW HAVEN, Conn., Feb.
Sign-up for Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock investment picks
2015/2/9
By Tess Stynes Achillion Pharmaceuticals Inc. (ACHN) and Regulus Therapeutics Inc. (RGLS) provided updates on their early-stage trials of potential treatments for hepatitis C, with each drug developer saying its treatment shows promise.
Sign-up for Achillion Shares Rise, Regulus Falls After Hepatitis C Results investment picks
2014/12/22
- A six-week dual NS5A – Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study") NEW HAVEN, Conn., Dec.
Sign-up for Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422 investment picks
2015/2/6
NEW HAVEN, Conn., Feb.
Sign-up for Achillion to Present at Two Upcoming Investor Conferences investment picks
2015/2/17
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1175463&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Achronix Announces Production Availability of Speedster22i Product Family investment picks
2015/2/18
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1175561&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Achronix Dramatically Reduces Compile Times With New Incremental Compile Support in Its ACE Design Tools investment picks
2015/2/3
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , has confirmed its commitment to the continuing development of ReD Shield®, its flagship eCommerce fraud prevention solution.
Sign-up for ACI Worldwide Confirms Commitment to ReD Shield with Multimillion Dollar Investment Plans investment picks
2015/1/26
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced new and advanced capabilities within its market-leading bill payment platform , UP Bill Payment Solutions, that elevate customer engagement by 30 percent.* To spark revenue growth and cost reduction, UP Bill Payment Solutions now feature videos and actionable offers embedded in electronic bills (eBills). Competition to win customers’ attention and loyalty is increasing—with the cost to capture customer attention alone growing tenfold*. Yet most organizations do not capitalize on their most frequent customer touch point, their bill.
Sign-up for ACI Worldwide Drives 30 Percent Increase in Customer Engagement by Revolutionizing the Bill Pay Experience investment picks
2015/1/20
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced a strategic partnership with LD Systems, an international provider of ATMs, financial equipment and technology services.
Sign-up for ACI Worldwide Partners with LD Systems to Deliver Flexible Kiosk Payment Solution investment picks
2015/2/11
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced the expansion of its relationship with PKO BP, the largest bank in Poland.
Sign-up for ACI Worldwide Powers Payments at PKO BP, Poland’s Largest Bank investment picks
2015/1/6
ACI Worldwide (NASDAQ: ACIW), a leading global provider of electronic payment and banking solutions , today announced its participation at NRF's Annual Convention & Expo, January 11-13, 2015 in New York City.
Sign-up for ACI Worldwide Showcases EMV Readiness at NRF 2015 investment picks
2015/2/12
ACI Worldwide (NASDAQ:ACIW), a leading global provider of electronic payment and banking solutions , announced today that it will report its financial results for the fourth quarter and full year 2014 on February 26, 2015.
Sign-up for ACI Worldwide, Inc. to Release Fourth Quarter and Full Year 2014 Financial Results investment picks
2015/2/4
Acklands-Grainger Hosts "The Works" Canada's Largest MRO and Safety Product Expo Canada NewsWire Company demonstrates commitment to Canadian industry with its ninth national show VANCOUVER, British Columbia , Feb.
Sign-up for Acklands-Grainger Hosts "The Works" Canada's Largest MRO and Safety Product Expo investment picks
2014/12/15
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD). “Approximately three and a half million stroke survivors in the U.S. suffer ongoing mobility issues.
Sign-up for Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits investment picks
2014/12/10
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson’s disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move.
Sign-up for Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease investment picks
2015/2/2
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied.
Sign-up for Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis investment picks
2015/1/12
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2014 were $109 million, and unaudited AMPYRA 2014 full-year net sales were $366 million, an increase of approximately 21% from 2013.
Sign-up for Acorda Provides Corporate Update at J.P. Morgan Healthcare Conference investment picks
2015/2/12
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced its financial results for the fourth quarter and full year ended December 31, 2014.
Sign-up for Acorda Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results investment picks
2015/2/5
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will host a conference call and live webcast to report its fourth quarter and year end 2014 financial results on Thursday, February 12 at 8:30 a.m. ET.
Sign-up for Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2014 Financial Results on February 12, 2015 investment picks
2015/2/5
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 2015 Leerink Global Healthcare Conference in New York on Thursday, February 12 at 1:50pm. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com , or you may use the link: http://leerink.metameetings.com/confbook/healthcare15/directlink?ticker=ACOR Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection.
Sign-up for Acorda Therapeutics to Present at the 2015 Leerink Global Healthcare Conference investment picks
2015/2/17
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Ron Cohen, President and Chief Executive Officer, will present at the RBC Capital Markets’ Healthcare Conference in New York on Tuesday, February 24 at 11:00am. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com or you may use the link: http://www.veracast.com/webcasts/rbc/healthcare2015/16107325299.cfm Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection.
Sign-up for Acorda Therapeutics to Present at the 2015 RBC Capital Markets’ Healthcare Conference investment picks
2014/12/2
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2 at 11:00am. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com , or you may use the link: http://www.media-server.com/m/p/e2k2247a Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection.
Sign-up for Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
2015/2/23
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Ron Cohen, President and Chief Executive Officer, will present at the Cowen 35th Annual Health Care Conference in Boston on Monday, March 2 at 2:10pm. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com or you may use the link: http://wsw.com/webcast/cowen22/acor .
Sign-up for Acorda Therapeutics to Present at the Cowen 35th Annual Health Care Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ACETO Corporation Schedules Second Quarter Fiscal 2015 Financial Results News Release and Conference Call to Acorda Therapeutics to Present at the Cowen 35th Annual Health Care Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent